A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin αvβ3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

The present disclosure sets forth novel compounds and compositions including heteroaromatic silicon-fluoride-acceptors, which are useful for PET scanning. The present disclosure further includes novel methods of .sup.8F imaging for PET scanning, the methods comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In certain embodiments the invention is practiced in the form of a kit.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R.sup.0 is O or S. Each of R.sup.1a, R.sup.1b and R.sup.1c may be —CO.sub.2H, —SO.sub.2H, —SO.sub.3H, —PO.sub.2H, or —PO.sub.3H.sub.2, for example. R.sup.2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R.sup.3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

##STR00001##

The present invention includes novel compounds and compositions including heteroaromatic Silicon-Fluoride-Acceptors, which are useful for PET imaging, as well as methods for making and using these compounds. The present invention further includes methods of .sup.18F imaging for PET scanning. In one embodiment the invention is practiced in the form of a kit.

The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.

##STR00001##

A light emitting device includes a first electrode, a second electrode disposed on the first electrode, and a light emitting layer disposed between the first electrode and the second electrode. The light emitting layer includes a novel polycyclic compound and thus, the light emitting device may exhibit high light emission efficiency properties and improved lifespan properties.

A compound comprising a first ligand L.sub.A of Formula I,

##STR00001##

in provided. In Formula I, moiety X is a fused multicyclic ring system comprising two or more rings; rings A and B are independently a 5- or 6-membered carbocyclic or heterocyclic ring; Z.sup.1, Z.sup.2, and Z.sup.3 are each C or N; K.sup.3 and K.sup.4 are each a direct bond, O, or S; each R.sup.A, R.sup.B, and R.sup.X is hydrogen or a substituent; and at least one of the following conditions is true: (1) ring B is partially or fully deuterated, or (2) at least one R.sup.B is an aryl or heteroaryl group that is partially or fully deuterated. The ligand L.sub.A is coordinated to a metal M through the dashed lines, and any two substituents except an R.sup.X with an R.sup.B may be joined to form a ring. Formulations, OLEDs, and consumer products containing these compounds are also provided.

The present disclosure belongs to the field of organic electroluminescent materials, and specifically relates to a nitrogen-containing compound, an electronic component using the nitrogen-containing compound and an electronic device using the nitrogen-containing compound. The nitrogen-containing compound has a structure as shown in Formula 1. When the nitrogen-containing compound of the present disclosure is used in an organic electroluminescent device, properties of the device can be effectively improved.

##STR00001##

Methods for rapid, efficient, and safe fluoridation and radiolabeling of established and new biomarkers are described. More specifically, the described herein methods may be used for fluoridation of biomarkers or to facilitate isotopic exchanges, especially .sup.19F/.sup.18F IEX, for rapid and efficient manufacturing of radiotracers, including radiotracers for positron emission tomography (PET), under clinically relevant conditions.

Disclosed is a novel organometallic compound represented by following Chemical Formula 1. The organometallic compound acts as a dopant of a phosphorescent light-emitting layer of an organic light-emitting diode. Thus, an operation voltage of the diode is lowered, and luminous efficiency and a lifespan thereof are improved, and red-shift is suppressed:

##STR00001##